Zydus Wins US Nod for Celecoxib

  Published 10 months ago

Zydus Lifesciences gets USFDA nod to market Celecoxib capsules, expanding its US portfolio; US sales total $122.6 million.

  • Celecoxib treats arthritis, menstrual pain, and juvenile rheumatoid arthritis in children over 2 years old.
  • Capsules to be produced at Zydus Lifesciences’ Ahmedabad facility; boosts company’s U.S. generics business.
  • With this nod, Zydus holds 428 USFDA final approvals and has filed 492 ANDAs since FY 2003-04.

You might like these

Oberoi Realty Q2 FY26 Profit Surge

Middle East Tensions Spook Markets, Crude Surges 9%

IndusInd Bank Expands PIONEER Network for HNIs

TCC Concept Acquires Pepperfry

Royal Orchid Hotels Rises on New Property Launch in Solapur

Sensex, Nifty Edge Up; ITC Gains, IT Drags

Sonata Software Q1 Revenue Rises 17%

News that matters the most ⚡